Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using PD-1/PD-L1 inhibitors often face resistance due to tumors expressing both CSF1R-expressing tumor-associated macrophages and PD-1-expressing CD8+ T cells, which limits their efficacy.
Innovation Solution
Administering a combination of anti-CSF1R antibodies and PD-1/PD-L1 inhibitors, where the anti-CSF1R antibodies can inhibit CSF1R signaling, thereby reducing immunosuppressive macrophages and enhancing the effectiveness of PD-1/PD-L1 inhibitors by boosting PD-1-expressing CD8+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 inhibitors are used as monotherapy, then treatment is simple and cost-effective, but tumor resistance develops due to immunosuppressive macrophages expressing CSF1R
Solution Approach 1:
The patent combines anti-CSF1R antibodies with anti-PD-1/PD-L1 inhibitors into a dual-target therapy regimen. This merging of two mechanisms addresses tumor resistance by simultaneously blocking immunosuppressive macrophage activity via CSF1R inhibition and enhancing T cell response via PD-1/PD-L1 blockade, thereby improving treatment efficacy while managing the complexity through coordinated administration
2Reliability
If combination therapy with anti-CSF1R antibodies and PD-1/PD-L1 inhibitors is administered, then treatment efficacy is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent employs preliminary action by first identifying tumors with high CSF1R-expressing macrophage infiltration through biomarker assessment. This pre-screening allows selective application of the complex combination therapy to patients most likely to benefit, thereby managing treatment complexity while maximizing efficacy in the appropriate patient population
Solution Approach 2:
The patent incorporates feedback mechanisms through monitoring treatment response and tumor biomarker changes. By assessing patient response to combination therapy and adjusting treatment based on observed efficacy and tolerability, the system optimizes the complex regimen to maintain high effectiveness while adapting to individual patient needs
Data Source
AI summary
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.